A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2 in RSV-Seronegative Infants and Children

Official Title: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2 in RSV-Seronegative Infants and Children

Respiratory syncytial virus (RSV) is a common cause of illness in infants and children around the world. This study will evaluate the safety and immune response to an RSV vaccine in RSV-seronegative infants and children.

ClinicalTrials.gov ID: NCT02237209

Study Type: Interventional

Currently Recruiting Patients: No

Contact Information:

Margaret Ann Sanders

Research and Education Coordinator

312-227-8275

Specialties & Conditions

Patients & Visitors

Plan Your Visit

While You're Here

After Your Visit

Research Innovation

A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2 in RSV-Seronegative Infants and Children

Official Title: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2 in RSV-Seronegative Infants and Children

Contact Information:

Find

Get in Touch

Get to Know Us

For Healthcare Professionals